Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept

Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept

Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long‐term exte...

Full description

Bibliographic Details
Main Authors: Massimo Imazio, Allan L. Klein, Antonio Brucato, Antonio Abbate, Michael Arad, Paul C. Cremer, Antonella Insalaco, Martin M. LeWinter, Basil S. Lewis, David Lin, Sushil A. Luis, Stephen J. Nicholls, Paul Sutej, Yishay Wasserstrum, JoAnn Clair, Indra Agarwal, Sheldon Wang, John F. Paolini
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
autoinflammatory disease
interleukin‐1
recurrent pericarditis
rilonacept
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032516

Similar Items

Similar Items